PRLD — Prelude Therapeutics Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1678660 ·
Last close
$3.88
Market Cap
$252.17M
52W High
$6.83
52W Low
$1.15
ADV30
547,620
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,704,000 | — | -15,454,000 | -13,921,000 | 189,363,000 | 26,329,000 | 55,630,000 |
| Mar 2026 | 4,580,000 | — | -14,177,000 | -10,385,000 | 119,642,000 | 21,756,000 | 59,459,000 |
| Dec 2025 | 5,640,000 | — | -17,348,000 | -16,457,000 | 141,315,000 | 35,256,000 | 72,678,000 |
| Sep 2025 | 6,500,000 | — | -20,418,000 | -19,725,000 | 94,755,000 | 47,532,000 | 36,221,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,756,000
Investing CF
$-228,000
Financing CF
$24,662,000
CapEx
$-120,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.22
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-693,446,000
Inventory
—
Receivables
—
ST Investments
$59,798,000
EBIT TTM
$-84,137,000
Pretax Income TTM
$-77,798,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$22,424,000
EBITDA
$-64,510,000
Free Cash Flow
$-13,844,625
Enterprise Value
$338,639,712
Total Cash
$151,756,992
Total Debt
$17,650,000
Shares Out
65,075,350
Trailing EPS
$-0.73
Book Value
$1.30
ROE
-57.7%
ROA
-27.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,140,000 | -104,566,000 | -99,498,000 | 141,315,000 | 72,678,000 | 68,637,000 | -56,302,000 |
| Dec 2024 | 7,000,000 | -139,714,000 | -127,173,000 | 175,515,000 | 44,056,000 | 131,459,000 | -102,888,000 |
| Dec 2023 | 0 | -132,277,000 | -121,832,000 | 277,665,000 | 40,575,000 | 237,090,000 | -107,063,000 |
| Dec 2022 | 0 | -123,540,000 | -115,438,000 | 220,500,000 | 25,063,000 | 195,437,000 | -83,729,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.75
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.88 · call volume: 203 · put volume: 2
Expected Move to 2026-10-16:
±$0.95
(24.52%) —
implied range
$2.92 –
$4.83
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACIU | AC Immune SA | $250.56M | $2.52 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $255.61M | $2.70 | — |
| AKBA | Akebia Therapeutics, Inc. | $248.29M | $0.90 | — |
| SIGA | SIGA TECHNOLOGIES INC | $247.88M | $3.45 | — |
| CAMP | Camp4 Therapeutics Corp | $245.99M | $3.92 | — |
News headlines (Yahoo Finance, 1h cache)
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-11 11:01 · Yahoo
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
2026-09-10 11:01 · Yahoo
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
2026-07-17 16:00 · Yahoo
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
2026-05-31 10:55 · Yahoo
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
2026-05-16 14:22 · Yahoo
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 11:01 · Yahoo
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
2026-05-08 13:55 · Yahoo
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
2026-05-01 09:24 · Yahoo
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cance
2026-04-20 10:00 · Yahoo
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
2026-04-15 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.